Orlistat (also known as tetrahydrolipstatin) is a drug designed to treat obesity. It is marketed as a prescription drug under the trade name Xenical by Roche in most countries, and is sold over-the-counter as Alli[2] by GlaxoSmithKline in the United Kingdom and the United States.[3] Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.[4]

Starting at
| (S)-((S)-1-((2S,3S)-3-Hexyl-4-oxooxetan-2-yl)tridecan-2-yl) 2-formamido-4-methylpentanoate |
| Trade names | Xenical, alli |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a601244 |
| Licence data | EMA:Link, US FDA:link |
| Pregnancy category |
AU: B1 US: X (Contraindicated) |
| Legal status |
AU: S3 (Pharmacist only) UK: Pharmacy medicines US: OTC |
| Routes of administration |
Oral |
| Bioavailability | Negligible[1] |
| Protein binding | >99% |
| Metabolism | In the GI tract |
| Biological half-life | 1 to 2 hours |
| Excretion | Fecal |
| CAS Number | 96829-58-2 |
| ATC code | A08AB01 |
| PubChem | CID: 3034010 |
| IUPHAR/BPS | 5277 |
| DrugBank | DB01083 |
| ChemSpider | 2298564 |
| UNII | 95M8R751W8 |
| KEGG | D04028 |
| ChEMBL | CHEMBL175247 |
| Formula | C29H53NO5 |
| Molecular mass | 495.735 g/mol |
|
SMILES[show] |
|
|
InChI[show] |
|